SEC Form 4 · accession 0001179022-18-000047
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold H. Shlevin
Officer — Chief Operating Officer
Period of report
Jun 6, 2018
Accepted (ET)
Jun 8, 2018 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 6, 2018 | M | 4,180 | $2.32 | A | 58,094 | D | |
| Common Stock | Jun 6, 2018 | M | 4,898 | $0.87 | A | 62,992 | D | |
| Common Stock | Jun 6, 2018 | S | 9,078 | $5.15 | D | 53,914 | D | |
| Common Stock | Jun 7, 2018 | M | 75,190 | $2.32 | A | 129,104 | D | |
| Common Stock | Jun 7, 2018 | M | 25,701 | $0.87 | A | 154,805 | D | |
| Common StockF4 | Jun 7, 2018 | S | 100,891 | $5.2063 | D | 53,914 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $2.32 | Jun 6, 2018 | M | 4,180 | D | — | Aug 27, 2022 | Common Stock | 4,180 | 75,190 | D |
| Stock option (right to buy)F3 | $0.87 | Jun 6, 2018 | M | 4,898 | D | — | Dec 3, 2026 | Common Stock | 4,898 | 75,701 | D |
| Stock option (right to buy)F2 | $2.32 | Jun 7, 2018 | M | 75,190 | D | — | Aug 27, 2022 | Common Stock | 75,190 | 0 | D |
| Stock option (right to buy)F3 | $0.87 | Jun 7, 2018 | M | 25,701 | D | — | Dec 3, 2026 | Common Stock | 25,701 | 50,000 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018.
- F2The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014.
- F3The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
- F4The shares were sold in multiple transactions at prices ranging from $5.15 to $5.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.